Supernus Pharmaceuticals (SUPN) Return on Capital Employed (2012 - 2025)
Supernus Pharmaceuticals' (SUPN) quarterly Return on Capital Employed came in at 5.67% in Q4 2025, down 1335.0% year-on-year from 0.46% in Q4 2024, and down 64.37% on a QoQ basis from 3.45% in Q3 2025.
Supernus Pharmaceuticals (SUPN) Return on Capital Employed (2012 - 2025) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 14 years of Return on Capital Employed data on file, last reported at 5.67% in Q4 2025.
- On a quarterly basis, Return on Capital Employed fell 1335.0% year-over-year to 5.67% in Q4 2025; TTM through Dec 2025 was 5.67%, a 1335.0% decrease from a year earlier, with the FY2025 full-year figure at 5.81%, down 1373.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 5.67%, down from 3.45% in the prior quarter.
- Over the last five years, Return on Capital Employed for SUPN reached as high as 11.65% in Q2 2021 and fell as low as 5.67% in Q4 2025.
- Historically, Return on Capital Employed has averaged 4.17% across 5 years, with a median of 5.14% in 2022.
- Across the five-year window, Return on Capital Employed tumbled 2712 bps in 2021 and soared 832 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 6.58% in 2021, then sank by 31 bps to 4.57% in 2022, then plunged by 112 bps to 0.53% in 2023, then soared by 1545 bps to 7.68% in 2024, then plunged by 174 bps to 5.67% in 2025.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 5.67% in Q4 2025, 3.45% in Q3 2025, and 5.95% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Supernus Pharmaceuticals | 2.72 Bn | 2.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.67% |
| Sep 30, 2025 | -3.45% |
| Jun 30, 2025 | 5.95% |
| Mar 31, 2025 | 6.93% |
| Dec 31, 2024 | 7.68% |
| Sep 30, 2024 | 5.71% |
| Jun 30, 2024 | 2.65% |
| Mar 31, 2024 | -1.39% |
| Dec 31, 2023 | -0.53% |
| Sep 30, 2023 | 3.00% |
| Jun 30, 2023 | 1.58% |
| Mar 31, 2023 | 4.86% |
| Dec 31, 2022 | 4.57% |
| Sep 30, 2022 | 1.85% |
| Jun 30, 2022 | 5.58% |
| Mar 31, 2022 | 5.42% |
| Dec 31, 2021 | 6.58% |
| Sep 30, 2021 | 9.25% |
| Jun 30, 2021 | 11.65% |
| Mar 31, 2021 | 11.18% |